NASDAQ:ACRS

Aclaris Therapeutics Stock Insider Trading

Healthcare > Medical - Diagnostics & Research

Buy ACRS

*Your capital is at risk

$4.42

-0.210 (-4.54%)

At Close: Jun 03, 2026

Aclaris Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 31.24. In total, the insiders bought 6.16M and sold 449.42K ACRS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	31.24
● Buy	6.16M shares
● Sell	449.42K shares
85% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence Apr 23, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 31.24. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Sell	Common Stock F-InKind	Hall Jesse Wayne Chief Medical Officer	Officer	9 330 Value: $41.1K
May 01, 2026 Buy	Common Stock M-Exempt	Hall Jesse Wayne Chief Medical Officer	Officer	36 375 Value: $160.4K
May 01, 2026 Buy	Restricted Stock Units M-Exempt	Hall Jesse Wayne Chief Medical Officer	Officer	36 375 Value: $160.4K
Apr 23, 2026 Sell	Common Stock S-Sale	Leonard Braden Michael 10 Percent Owner	10% Owner	300 000 Value: $1.36M
Mar 01, 2026 Buy	Restricted Stock Units M-Exempt	Balthaser Kevin Chief Financial Officer	C-Suite Officer	2 375 Value: $10.5K
Mar 01, 2026 Sell	Common Stock F-InKind	Balthaser Kevin Chief Financial Officer	C-Suite Officer	677 Value: $2K
Mar 01, 2026 Buy	Common Stock M-Exempt	Balthaser Kevin Chief Financial Officer	C-Suite Officer	2 375 Value: $10.5K
Feb 03, 2026 Buy	Restricted Stock Units M-Exempt	Balthaser Kevin Chief Financial Officer	C-Suite Officer	22 025 Value: $76.4K
Feb 03, 2026 Sell	Common Stock F-InKind	Balthaser Kevin Chief Financial Officer	C-Suite Officer	6 449 Value: $22.4K
Feb 03, 2026 Buy	Common Stock M-Exempt	Balthaser Kevin Chief Financial Officer	C-Suite Officer	22 025 Value: $76.4K
Feb 03, 2026 Buy	Common Stock M-Exempt	Walker Neal CEO	CEO / President	63 475 Value: $220.3K
Feb 03, 2026 Buy	Restricted Stock Units M-Exempt	Loerop James Chief Business Officer	Officer	20 875 Value: $72.4K
Feb 03, 2026 Sell	Common Stock F-InKind	Loerop James Chief Business Officer	Officer	5 937 Value: $20.6K
Feb 03, 2026 Buy	Common Stock M-Exempt	Loerop James Chief Business Officer	Officer	20 875 Value: $72.4K
Feb 03, 2026 Sell	Common Stock F-InKind	Walker Neal CEO	CEO / President	18 611 Value: $64.6K
Feb 03, 2026 Buy	Restricted Stock Units M-Exempt	Walker Neal CEO	CEO / President	63 475 Value: $220.3K
Feb 03, 2026 Buy	Restricted Stock Units M-Exempt	Davis Hugh M. President And COO	CEO / President	18 675 Value: $64.8K
Feb 03, 2026 Buy	Common Stock M-Exempt	Davis Hugh M. President And COO	CEO / President	18 675 Value: $64.8K
Feb 02, 2026 Buy	Restricted Stock Units A-Award	Balthaser Kevin Chief Financial Officer	C-Suite Officer	99 100 Value: $357.8K
Feb 02, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Balthaser Kevin Chief Financial Officer	C-Suite Officer	346 800 Value: $1.25M
Feb 02, 2026 Buy	Restricted Stock Units A-Award	Loerop James Chief Business Officer	Officer	97 700 Value: $352.7K
Feb 02, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Loerop James Chief Business Officer	Officer	341 900 Value: $1.23M
Feb 02, 2026 Buy	Restricted Stock Units A-Award	Hall Jesse Wayne Chief Medical Officer	Officer	98 100 Value: $354.1K
Feb 02, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Hall Jesse Wayne Chief Medical Officer	Officer	343 300 Value: $1.24M
Feb 02, 2026 Buy	Restricted Stock Units A-Award	Kolbeck Roland Wilhelm Chief Scientific Officer	Officer	95 700 Value: $345.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ACLARIS THERAPEUTICS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of...

Read Full Profile Here